News

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

  • Seven IPOs and three SPACs were listed this week. Seven IPOs and four SPACs submitted initial filings. Some small IPOs are tentatively scheduled for the short holiday week ahead.
    02/14/2025

Aardvark Therapeutics Announces Pricing of Initial Public Offering

  • SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the pricing of its initial public offering of 5,888,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Aardvark. The gross proceeds to Aardvark from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $94.2 million. Aardvark's common stock is expected to begin trading on the Nasdaq Global Select Market on February 13, 2025 under the ticker symbol “AARD.” The offering is expected to close on February 14, 2025, subject to the satisfaction of customary closing conditions. In addition, Aardvark has granted the underwriters a 30-day option to purchase up to an additional 883,200 shares of common stock at the public offering price, less underwriting discounts and commissions.
    02/12/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

The price of Aardvark Therapeutics, Inc. Common Stock (AARD) is 15.915 and it was updated on 2025-02-21 07:00:21.

Currently Aardvark Therapeutics, Inc. Common Stock (AARD) is in undervalued.

News
    
News

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

  • Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial Group, and Huachen AI Parking Management Technology. Eight IPOs are currently scheduled to list in the week ahead, although some small issuers may also join the calendar throughout the week.
    Sat, Feb. 08, 2025

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

  • Aardvark Therapeutics aims to raise $100 million in an IPO to fund its clinical-stage biopharma treatments for metabolic conditions, including Prader-Willi syndrome. Its lead candidate ARD-101, targeting hyperphagia, is entering Phase 3 trials with topline data expected in early 2026. The PWS market is projected to exceed $1 billion by 2034, presenting significant growth potential despite its rarity.
    Mon, Feb. 03, 2025
Press Releases
StockPrice Release

Aardvark therapeutics announces pricing of initial public offering

  • 02/12/2025
Unlock
AARD Ratings Summary
AARD Quant Ranking